Asset Licensing, clinical development, BD activities
JB
JD BIOSCIENCE
The startup develops small-molecule therapeutics that inhibit biogenesis in peripheral white adipose tissues, targeting metabolic complications associated with obesity and hard-to-treat diseases. Their therapies provide healthcare providers with effective treatment options where conventional medicines are lacking.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$19.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops small-molecule therapeutics that inhibit biogenesis in peripheral white adipose tissues, targeting metabolic complications associated with obesity and hard-to-treat diseases. Their therapies provide healthcare providers with effective treatment options where conventional medicines are lacking.